StockWatch
·
Biotechnology: Pharmaceutical Preparations
Management ChangeNov 20, 2026, 05:16 PM

MAINZ BIOMED N.V. Appoints David Caplon as New CFO; William Caragol Departs

AI Summary

MAINZ BIOMED N.V. announced the resignation of William Caragol as Chief Financial Officer, effective November 20, 2026. He will receive $15,000 per month as a consultant and retain his vested equity awards. David Caplon, previously the Company's Controller, has been appointed as the new Chief Financial Officer. Caplon's new role includes serving as principal financial and accounting officer. His compensation package includes a base salary of $22,500 per month, a target annual bonus of 100% of his base salary, and annual equity awards. He was also granted an option to purchase 170,000 ordinary shares.

Key Highlights

  • William Caragol resigns as Chief Financial Officer of MAINZ BIOMED N.V., effective November 20, 2026.
  • David Caplon appointed as the new Chief Financial Officer, effective November 20, 2026.
  • Mr. Caragol to receive $15,000 per month as a consultant during the transition.
  • Mr. Caplon's new role includes serving as principal financial and accounting officer.
  • Mr. Caplon's base salary is $22,500 per month ($270,000 annually).
  • Mr. Caplon is eligible for a target annual bonus of 100% of his base salary.
  • Mr. Caplon granted an option to purchase 170,000 ordinary shares.
  • Mr. Caplon's employment agreement includes severance benefits and equity vesting acceleration under certain termination conditions.